세계의 섬유근육통 치료 시장 : 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Fibromyalgia Treatment Market was valued at USD 2.3 billion in 2024 and is estimated to grow at a CAGR of 4.2% to reach USD 3.4 billion by 2034, driven by a deeper understanding of fibromyalgia's complex pathophysiology, including neurochemical imbalances and central sensitization. Advances in diagnostic methods, such as quantitative sensory testing and the development of biomarkers for chronic pain syndromes, have improved early and accurate diagnosis. Integrating technology, including functional MRI and proteomic analysis, helps in identifying specific pain pathways and tailoring treatment strategies, thereby boosting market growth.

Additionally, incorporating artificial intelligence (AI)-powered platforms and digital health technologies has enhanced symptom tracking and management, enabling more personalized care approaches. The shift towards non-invasive treatments, such as neuromodulation and biofeedback, indicates a growing acceptance of holistic frameworks. Cross-industry collaboration among pharmaceutical companies, academic institutions, and clinical practitioners has catalyzed the development of advanced therapeutics, changing the course of treatment approaches and outcomes. The market encompasses pharmaceutical and non-pharmacological treatments aimed at managing chronic pain, fatigue, and associated symptoms of fibromyalgia, including medications like analgesics and antidepressants, as well as alternative therapies.

The medication segment generated USD 1.7 billion in 2024 due to increased patient expectations regarding pain, fatigue, and subsequent symptom management. Demand is rising for pharmacological approaches, which explains why the medication segment dominates the market. Key drug classes include antidepressants, anticonvulsants, and analgesic drugs that help patients enjoy a better quality of life. The growth in this segment is supported by the launch of new drugs and their reformulations, along with increased marketing authorizations of existing ones, such as pregabalin, one of the first FDA-approved drugs specifically for fibromyalgia.

Based on gender, the fibromyalgia treatment market is divided into male and female segments. The female segment accounted for a significant market share of 80.5% in 2024. The female segment represents a market share, as the condition disproportionately affects women. As reported by the National Center for Biotechnology Information (NCBI), fibromyalgia syndrome has a high female predominance, comprising 80%-96% of cases. These differences have been explained based on hormonal factors, greater pain perception, and variations in the functions of the nervous system.

U.S. Fibromyalgia Treatment Market was valued at USD 907.2 million in 2024 due to its quality healthcare system, high disease prevalence, and extensive pharmaceutical industry. FDA-approved drugs such as duloxetine, milnacipran, and pregabalin dominate the prescription landscape. Patients are further motivated to seek treatment due to awareness programs and insurance coverage. Emerging trends include telemedicine for diagnosis and a shift toward a more personalized approach to medicine. Clinical research for new therapy approaches includes non-pharmaceutical options such as cognitive behavioral therapy and lifestyle changes.

Major players operating in the Global Fibromyalgia Treatment Industry include Abbott Laboratories, AbbVie, Amneal Pharmaceuticals, AstraZeneca, Colorado Fibromyalgia Center, Eli Lilly and Company, Lupin, Mayo Clinic, Novartis, Pfizer, Sun Pharmaceutical, Teva Pharmaceutical, The General Hospital Corporation, UT Health Austin, Viatris, and Zydus Lifesciences. To strengthen their market foothold, companies in the fibromyalgia treatment sector are emphasizing innovation through robust investments in research and development. This includes advancing drug formulations, optimizing dosage regimens, and improving delivery technologies to increase patient adherence and therapeutic effectiveness. Many leading firms are also forming strategic alliances with academic institutions and research organizations to accelerate the discovery and commercialization of next-generation treatments.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of fibromyalgia globally
    • 3.2.1.2 Rising awareness about fibromyalgia diagnosis and treatment options
    • 3.2.1.3 Advances in pharmaceutical therapies targeting pain management
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of advanced fibromyalgia treatments
    • 3.2.2.2 Limited availability of effective medications specifically approved for fibromyalgia
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the Industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021-2034 ($ Mn)

• 5.1 Key trends
• 5.2 Medication
  • 5.2.1 Antidepressants
  • 5.2.2 Anticonvulsants
  • 5.2.3 Analgesics
  • 5.2.4 Muscle relaxants
  • 5.2.5 Other medications
• 5.3 Therapy
  • 5.3.1 Physical therapy
  • 5.3.2 Occupational therapy
  • 5.3.3 Other therapies

Chapter 6 Market Estimates and Forecast, By Gender, 2021-2034 ($ Mn)

• 6.1 Key trends
• 6.2 Male
• 6.3 Female

Chapter 7 Market Estimates and Forecast, By End Use, 2021-2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021-2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 AbbVie
• 9.3 Amneal Pharmaceuticals
• 9.4 AstraZeneca
• 9.5 Colorado Fibromyalgia Center
• 9.6 Eli Lilly and Company
• 9.7 Lupin
• 9.8 Mayo Clinic
• 9.9 Novartis
• 9.10 Pfizer
• 9.11 Sun Pharmaceutical
• 9.12 Teva Pharmaceutical
• 9.13 The General Hospital Corporation
• 9.14 UT Health Austin
• 9.15 Viatris
• 9.16 Zydus Lifesciences